Up | AC Home Page

Oncologic Drugs Advisory Committee

May 9, 2007

BREIFING INFORMATION

Morning Session

IDM Pharma, Inc.

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

IDM Pharma, Inc. Briefing Material for NDA 022-092 mifamurtide (pdf)

FDA

Disclaimer

Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).
These redacted portions will appear as white space on the screen or on the printed page.

FDA Briefing Material for Mifamurtide (pdf)

Errata - FDA Briefing Document Mifamurtide (htm)

Afternoon Session

DOR BioPharma, Inc.

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

DOR BioPharma, Inc.  NDA 022-062 orBec (oral beclamethasone diproprionate, BDP) (pdf)

Errata for DOR BioPharma, Inc.  NDA 022-062 orBec (htm)

FDA

Disclaimer

Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552). These redacted portions will appear as white space on the screen or on the printed page.

FDA Briefing Material for NDA 022-062 orBec (pdf)

Errata Briefing Material for NDA 022-062 orBec (htm)

---